-
Biogen IDEC Earnings Preview: Analysts Expect Falling Revenue Over Last Quarter
Thursday, July 21, 2011 - 1:43pm | 529Biogen IDEC (NASDAQ: BIIB) unveils its next round of earnings this Tuesday, July 26, 2011. Here is Benzinga's everything-that-matters guide for this Tuesday's second quarter earnings report. Earnings and Revenue: Analysts are predicting a positive EPS reading of $1.37 per share and revenues of $1...
-
Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter
Thursday, July 21, 2011 - 1:12pm | 599Gilead Sciences (NASDAQ: GILD) announces its next round of earnings this Tuesday, July 26, 2011. Here's Benzinga's guide to Gilead Sciences' second quarter earnings report. Earnings and Revenue: Ahead of the company's earnings announcement, analysts are expecting a positive EPS reading of 96...
-
Gilead Sciences Hits New 52-Week High at $42.94
Thursday, July 21, 2011 - 1:00pm | 76Many traders and investors see the 52-week high or low as an important indicator. Stocks that have a long-term trend in a certain direction are likely to continue, as that trend is the path of least resistance. In this case, shares of Gilead Sciences (NASDAQ: GILD) are hitting new 52-week highs....
-
Neuralstem Receives Russian Patent for Stem Cell Transplantation to Treat Neurodegenerative Conditions
Thursday, July 21, 2011 - 12:22pm | 191Neuralstem, Inc. (NYSE: CUR) announced that it has received a patent covering the transplantation of human neural cells for the treatment of neurodegenerative conditions from the Russian Federation. The claims include methods of culturing the cells as well as treating amyotrophic lateral sclerosis...
-
Pharma and Biotech News; BioSante Pharmaceuticals Signs Melanoma Vaccine License
Thursday, July 21, 2011 - 11:25am | 1051LINCOLNSHIRE, Ill. - July 21, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening...
-
Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
Thursday, July 21, 2011 - 9:30am | 165Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. Both products are indicated for the...
-
Celsion Corporation Announces $18.4 Million in Financing
Thursday, July 21, 2011 - 8:36am | 229Celsion Corporation (NASDAQ: CLSN) today announced that it has received commitments from investors to purchase an aggregate of $18.4 million of the Company's securities, of which $13.0 million are from institutional investors in a registered direct offering and an additional $5.4 million are from...
-
BioSante Pharmaceuticals Signs Melanoma Vaccine License
Thursday, July 21, 2011 - 7:55am | 109BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities. BioSante received $100...
-
Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer
Thursday, July 21, 2011 - 7:21am | 148Repligen Corporation (NASDAQ: RGEN) today announced that the first patient has been enrolled in a pilot study to evaluate the ability of RG1068 to improve detection and characterization of pancreatic cancer in combination with contrast-enhanced magnetic resonance imaging (MRI) and computed...
-
UPDATE: Noble Downgrades Pharmasset to Hold
Thursday, July 21, 2011 - 7:17am | 109Noble is out with its report today on Pharmasset (NASDAQ: VRUS), downgrading VRUS from Buy to Hold. In a note to clients, Noble writes, "We are moving from a Buy to a Hold based upon the firm's current valuation and more than a 300% move since January of 2011. At the current market capitalization...
-
Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease Technology
Thursday, July 21, 2011 - 7:13am | 104Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of a study demonstrating the use of zinc finger nucleases to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences, represents a significant advancement in the...
-
Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes
Thursday, July 21, 2011 - 7:12am | 107Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B. ISIS-PTP1BRx is designed to increase the body's sensitivity to the...
-
Noble Downgrades VRUS To Hold
Thursday, July 21, 2011 - 7:03am | 19Noble Research has downgraded Pharmasset (NASDAQ: VRUS) from Buy to Hold.
-
Stocks to Watch for Thursday 7/21/2011: Fresh 52 Week Highs and Lows
Thursday, July 21, 2011 - 5:36am | 2699Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Wednesdays's trading session (listed from highest total volume to lowest): 1) Nalco Holding (NYSE: NLC): Shares...
-
Idera Reports Clinical Hold on Proposed Phase 2 Clinical Trial of IMO-3100
Wednesday, July 20, 2011 - 5:00pm | 184Idera Pharmaceuticals (Nasdaq: IDRA) today announced the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that a proposed Phase 2 protocol that the Company had recently submitted under an Investigational New Drug Application for IMO-3100 will be placed on a...